The quantification of phosphorylated tau in biofluids, either cerebrospinal fluid (CSF) or
plasma, has shown great promise in detecting Alzheimer’s disease (AD) pathophysiology. Tau …

Whilst cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers for
amyloid-β (Aβ) and tau pathologies are accurate for the diagnosis of Alzheimer’s disease (AD), …

Importance Plasma phosphorylated tau at threonine 181 (p-tau181) has been proposed as
an easily accessible biomarker for the detection of Alzheimer disease (AD) pathology, but its …

Tau phosphorylated at threonine 181 (p-tau181) measured in blood plasma has recently
been proposed as an accessible, scalable, and highly specific biomarker for Alzheimer’s …

Alzheimer's disease is characterized by the accumulation and deposition of plaques of β-amyloid
(Aβ) peptide in the brain. Given its pivotal role, new therapies targeting Aβ are in …

Introduction We tested how tube types (ethylenediaminetetraacetic acid [EDTA], serum, lithium
heparin [LiHep], and citrate) and freeze–thaw cycles affect levels of blood biomarkers for …

Alzheimer’s disease (AD) is increasingly prevalent worldwide, and disease‐modifying
treatments may soon be at hand; hence, now, more than ever, there is a need to develop …

Objective To study CSF biomarkers of Alzheimer disease (AD) analyzed by fully automated
Elecsys immunoassays compared to neuropathologic gold standards and to compare their …

Follow-up of β-amyloid (Aβ) deposition in transgenic mouse models of Alzheimer disease (AD)
would be a valuable translational tool in the preclinical evaluation of potential …

Mouse models of Alzheimer's disease (AD) are valuable but do not fully recapitulate human
AD pathology, such as spontaneous Tau fibril accumulation and neuronal loss, …